

1 **Short-Term Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-**
2 **19 Vaccinations in South Korea**

3 **Running title:** Vaccine Effectiveness of NVX-CoV2373

4 **Authors:** Eunseon Gwak^{1*}, Seung-Ah Choe^{1,2*}, Erdenetuya Bolormaa¹, Young June Choe¹,
5 Chengbin Wang³, Jonathan Fix³, Muruga Vadivale³, and Matthew D. Rousculp³

6 **Affiliations:** ¹Korea University College of Medicine, Seoul, Korea; ²Research and management
7 center for health risk of particulate matter, Korea University, Seoul, Korea; ³Novavax, Inc.,
8 Gaithersburg, MD, USA.

9 *Equally contributed to the manuscript

10 **Correspondence:** Young June Choe, MD, PhD. Department of Pediatrics, Korea University
11 College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Korea. Tel: +82-2-920-5090;
12 Email: choey@korea.ac.kr; Matthew D. Rousculp, PhD, Real World Evidence, Novavax, Inc., 21
13 Firstfield Rd, Gaithersburg, MD 20878. Email: mrousculp@novavax.com

14

15

16

17

18

19

20 **Abstract:**

21

22 To estimate the relative, short-term effectiveness of NVX-CoV2373 versus BNT162b2 (Pfizer–
23 BioNTech) in preventing SARS-CoV-2 infection and severe COVID-19 disease during the
24 Omicron variant dominance in South Korea. Retrospective cohort-study among ≥ 12 -year-olds
25 using the K-COV-N database, which links COVID-19 vaccine registry data with health insurance
26 claims data. The Cox proportional-hazards model and inverse probability of treatment weighting
27 were employed to calculate adjusted hazard ratios (aHRs). Among homologous primary-series
28 NVX-CoV2373 versus BNT162b2 recipients, the aHR was 0.86 (95% CI: 0.82–0.91) for all
29 laboratory-confirmed and 0.80 (95% CI: 0.48–1.33) for severe infections. Among homologous
30 1st-booster recipients, it was 0.74 (95% CI: 0.61–0.90) for all laboratory-confirmed and 0.48 (95%
31 CI: 0.12–1.92) for severe infections. At 30-days post-immunization, we observed homologous,
32 NVX-CoV2373 primary-series and 1st-booster offered added protection against SARS-CoV-2
33 infection versus BNT162b2; while there was numerically lower risk of severe disease among
34 NVX-CoV2373-vaccinated, no statistically significant differences were observed.

35

36 **Introduction:**

37 NVX-CoV2373, a monovalent protein-based SARS-CoV-2 vaccine demonstrated high
38 efficacy against coronavirus disease (COVID-19) in the United States and Mexico (1). As NVX-
39 CoV2373 is globally integrated into national immunization programs, including South Korea, it
40 is imperative to assess its real-world effectiveness against COVID-19. While evidence indicates
41 NVX-CoV2373 induces similar neutralizing antibody titers as COVID-19 mRNA vaccines, there
42 is limited data on its relative effectiveness in the general population (2). This study aims to
43 estimate the relative short-term effectiveness of NVX-CoV2373 compared to BNT162b2
44 (Pfizer–BioNTech) in preventing SARS-CoV-2 infection and critical COVID-19 during the
45 Omicron variant dominance in South Korea, using population-based data.

46

47 **Methods:**

48 We used the Korea Disease Control and Prevention Agency-COVID-19-National Health
49 Insurance Service (K-COV-N) cohort database that links the COVID-19 vaccine registry data
50 with the health insurance claims data (3). Vaccination status includes vaccination date, vaccine
51 type and dose, and place of vaccination. We then constructed a cohort to compare the risk of all
52 laboratory-confirmed and severe SARS-CoV-2 infections (intensive care unit [ICU] admission
53 due to COVID-19 or death within 30-days of SARS-CoV-2 infection) among the NVX-CoV2373
54 vaccine recipients compared with BNT162b2 recipients between February and December 2022.
55 Because the cause of death was unavailable in the data, death after SARS-CoV-2 infection within
56 the risk window was assumed to be related to it. The inclusion criteria capture all persons ≥ 12
57 years with known COVID-19 vaccination status, complete medical outcome data, at least 365-
58 days of follow-up before the index date (date of receiving a dose of interest), and residing in
59 South Korea. Our analysis was restricted only to individuals completing homologous primary or
60 booster series immunization.

61 We estimated propensity scores (PS) for receiving NVX-CoV2373 based on relative
62 income level (medical aid beneficiary and income quartiles), residential region (Seoul capital
63 area or not), disability registration, prior COVID-19 infection history, Charlson comorbidity
64 index assessed in the previous year, and month of the latest immunization. We used PS-based
65 inverse probability of treatment weighting (IPTW) to control for confounding by balancing
66 patient characteristics at baseline. We trimmed the tails of the IPTW distribution observations
67 below a PS of 5% and above a PS of 95% of the vaccinated cohorts, thereby excluding those

68 with extreme values (4). To compare vaccine effectiveness (VE), we estimated the incidence rate
69 (IR per 1000 person-days) and IPTW-adjusted hazard ratios (aHR) of all laboratory-confirmed
70 and severe SARS-CoV-2 infections considering time-varying exposures to vaccination.

71 The risk window for outcomes was 30-days (NOTE: The risk window started either after
72 7 days (booster) or 14 days (primary series) post-vaccination). For each outcome, individuals
73 were followed for the duration of the risk window until the earliest of one of the following:
74 documentation of the COVID-19 morbidity, death, maximum follow-up duration (30-days), next
75 dose administration, and the end of the study calendar period (December 31, 2022).

76 The relative VE of NVX-CoV2373 vaccination versus BNT162b2 was assessed
77 regarding overall and severe SARS-CoV-2 infections. The Cox proportional-hazards model was
78 employed to calculate the aHR of SARS-CoV-2 infection, and severe COVID-19 for NVX-
79 CoV2373 compared with BNT162b2. All statistical analyses were performed using SAS[®] 9.4
80 (SAS Institute, Cary, NC, USA). This study was approved by the Korea University Institutional
81 Review Board (IRB No. 2023AN0124).

82 **Results:**

83 Among the 137,845 recipients (104,004 for NVX-CoV2373 and 33,841 BNT162b2) of
84 homologous primary series, 17,134 and 4439 received homologous 1st booster doses, and 1,177
85 and 363 received homologous 2nd booster doses, respectively (Table 1). The NVX-CoV2373
86 recipients were older, more likely to be male, have a history of prior SARS-CoV-2 infection,
87 have a disability, be employed, and were found to have more comorbidities (CCI \geq 3), and higher
88 income level.

89 Table 2 showed IR and aHR of all laboratory-confirmed and severe SARS-CoV-2
90 infections following primary series, 1st booster, and 2nd booster of NVX-CoV2373 or BNT162b2
91 homologous doses. Among the homologous NVX-CoV2373 primary series recipients, 4884
92 (IR=1.53, 95% CI: 1.48–1.57) experienced an infection, with 58 (IR=0.02; 95% CI: 0.01–0.02)
93 having a severe infection. Among BNT162b2 primary series recipients, 4,249 (IR=4.36; 95% CI:
94 4.23–4.49) had laboratory-confirmed infections, and 34 (IR=0.03; 95% CI: 0.02–0.05)
95 experienced a severe infection. Comparing NVX-CoV2373 to BNT162b2, the aHR was 0.86 (95%
96 CI: 0.82–0.91) for all laboratory-confirmed and 0.80 (95% CI: 0.48–1.33) for severe infections.
97 Among homologous 1st booster recipients, the aHR was 0.74 (95% CI: 0.61–0.90) for all
98 laboratory-confirmed and 0.48 (95% CI: 0.12–1.92) for severe infections.

99 **Discussion:**

100 In this study, we observed that during the Omicron variant predominance in South Korea,
101 NVX-CoV2373 primary series offered added protection against laboratory-confirmed SARS-
102 CoV-2 infection than BNT162b2; while lower risk in NVX-CoV2373 in preventing severe
103 infection, but no statistical significance were observed. Comparable protection was observed
104 after the 1st booster doses of NVX-CoV2373 with BNT162b2, and no comparison was assessed
105 on the 2nd booster dose due to a lack of events after receiving the 2nd booster dose of NVX-
106 CoV2373 (Table 2). Our finding contrasts with a previous efficacy meta-analysis (5).
107 Nonetheless, our data represent the initial instance demonstrating the variation in effectiveness
108 for homologous doses (2 vs. 2, 3 vs. 3, and 4 vs. 4) of NVX-CoV2373 and BNT162b2 in a vast
109 population-based database.

110 Several limitations should be considered when interpreting the results. This study relied
111 on health insurance data and may lack information on all confounders, and the variant of
112 previous infections. Furthermore, time since previous infection might have been different across
113 NVX-CoV2373 and BNT162b2, However, the medical guidance in South Korea at the time was
114 to delay receipt of COVID-19 vaccine until 3 months after a confirmed SARS-CoV-2 infection,
115 as such the time since last infection is likely comparable between the two groups.

116 While we did not measure absolute VE against infection or severe disease compared to
117 unvaccinated, it provides valuable insights on the relative performance of a protein-based
118 vaccine platform compared to the mRNA platform and will help formulate public health
119 strategies. Based on prior immunological studies and our findings, it is advisable to assess the
120 overall benefits and risks of different vaccine platforms in the public's best interest (6).

121 In conclusion, our findings provide needed insight on short-term effectiveness of
122 different COVID-19 vaccine platforms. Furthermore, it underscores the importance for continued
123 vigilance to ensure increased COVID-19 vaccination coverage perhaps through broader vaccine
124 options.

125

126 **Funding**

127 This work was supported by Novavax, Inc. The sponsor had primary responsibility for study
128 design, protocol development, study monitoring, data management, and statistical analyses. All
129 authors reviewed and approved the manuscript before submission.

130

131 **Declaration of Competing Interest**

132 EG, EB, YJC, and SAC are investigators of the study and do not have any conflicts to report. JF,
133 MR, and MV are all employees of Novavax, Inc. and may hold stock in Novavax, Inc. CB used
134 to be employed by Novavax, Inc., and holds stock in Novavax, Inc.

135 **Acknowledgments**

136 This study used the Korea Disease Control and Prevention Agency (KDCA) and National Health
137 Insurance Service (NHIS) databases for policy and academic research (KDCA-NHIS-2023-1-
138 494). The conclusions of this study are not related to this institution.

139 **Contributions:**

140 Conceptualization and study design: EG, SC, EB, YJC, CW, and MDR. Data acquisition and
141 analysis: EG, SC, EB, and YJC. Data interpretation: EG, SC, EB, YJC, CW, JF, MV, and MDR.
142 Drafting of the manuscript and critical review: EG, SC, EB, YJC, CW, JF, MV, and MDR.

143 **References**

- 144 1. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al.
145 Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *The New*
146 *England journal of medicine*. 2022 Feb 10;386(6):531-43. PubMed PMID: 34910859. Pubmed
147 Central PMCID: PMC8693692. Epub 2021/12/16. eng.
- 148 2. Mateo-Urdiales A, Sacco C, Petrone D, Bella A, Riccardo F, Del Manso M, et al.
149 Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373

- 150 Against COVID-19. JAMA network open. 2023 Oct 2;6(10):e2336854. PubMed PMID:
151 37792377. Pubmed Central PMCID: PMC10551773. Epub 2023/10/04. eng.
- 152 3. Gwak E, Kim T, Shin JY, Choi NK, Han S, Lee JY, et al. Effectiveness and Safety of
153 COVID-19 Vaccination During Preconceptional and Preclinical Pregnancy Period: A National
154 Population Study. Journal of Korean medical science. 2023 Oct 23;38(41):e314. PubMed PMID:
155 37873626. Pubmed Central PMCID: PMC10593595. Epub 2023/10/24. eng.
- 156 4. Stürmer T, Webster-Clark M, Lund JL, Wyss R, Ellis AR, Lunt M, et al. Propensity
157 Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect
158 Estimates: A Simulation Study. American journal of epidemiology. 2021 Aug 1;190(8):1659-70.
159 PubMed PMID: 33615349. Pubmed Central PMCID: PMC8327194. Epub 2021/02/23. eng.
- 160 5. Wu X, Xu K, Zhan P, Liu H, Zhang F, Song Y, et al. Comparative efficacy and safety of
161 COVID-19 vaccines in phase III trials: a network meta-analysis. BMC infectious diseases. 2024
162 Feb 21;24(1):234. PubMed PMID: 38383356. Pubmed Central PMCID: PMC10880292. Epub
163 2024/02/22. eng.
- 164
- 165 6. Mai F, Kordt M, Bergmann-Ewert W, Reisinger EC, Müller-Hilke B. NVX-CoV2373
166 induces humoral and cellular immune responses that are functionally comparable to vector and
167 mRNA-based vaccines. Frontiers in immunology. 2024;15:1359475. PubMed PMID: 38562927.
168 Pubmed Central PMCID: PMC10982398. Epub 2024/04/02. eng.
- 169

Table 1. General characteristics of the population who received homologous series of NVX-CoV2373 and BNT162b2 vaccines in South Korea, from February to December 2022

Variables	Primary series			1st homologous booster			2nd homologous booster		
	NVX-CoV2373	BNT162b2	<i>P</i>	NVX-CoV2373	BNT162b2	<i>P</i>	NVX-CoV2373	BNT162b2	<i>P</i>
N	104,004	33,841		17,134	4439		1177	363	
Age, median	44 (IQR: 26)	36 (IQR: 23)	<0.001	57 (IQR: 29)	57 (IQR: 37)		68 (IQR: 16)	71 (IQR: 16)	
Sex									
Male	45,102 (43.4)	8293 (24.5)	<0.001	7767 (45.3)	1373 (30.9)	<0.001	631 (53.6)	211 (58.1)	0.131
Female	58,902 (56.6)	25,548 (75.5)		9367 (54.7)	3066 (69.1)		546 (46.4)	152 (41.9)	
Non-capital area ^a	52,397 (50.4)	17,163 (50.7)	0.282	8061 (47.1)	2072 (46.7)	0.66	506 (43)	167 (46)	0.311
Prior infection	80,559 (77.5)	21,391 (63.2)	<0.001	15,990 (93.3)	4003 (90.2)	<0.001	1175 (99.8)	355 (97.8)	<0.001
Disability	7896 (7.5)	2078 (6.1)	<0.001	2290 (13.4)	604 (13.6)	0.674	213 (18.1)	89 (24.5)	0.007
CCI ≥3	14,503 (13.9)	3312 (9.8)	<0.001	4000 (23.4)	924 (20.8)	<0.001	461 (39.2)	122 (33.6)	0.056
Employed	34,378 (33.1)	7781 (23.0)	<0.001	4362 (25.5)	683 (15.4)	<0.001	185 (15.7)	25 (6.9)	<0.001
Income level ^b									
1Q (lowest)	4750 (4.7)	1732 (5.4)	<0.001	1385 (8.3)	537 (12.5)	<0.001	138 (11.9)	79 (21.9)	<0.001
2Q	14,456 (14.4)	4107 (12.9)		2450 (14.6)	631 (14.7)		155 (13.4)	59 (16.4)	
3Q	20,019 (19.9)	6761 (21.2)		2988 (17.9)	834 (19.5)		184 (15.9)	61 (16.9)	
4Q	25,477 (25.3)	9783 (30.7)		3839 (23.0)	1111 (26.0)		222 (19.1)	73 (20.3)	
5Q (richest)	35,985 (35.7)	9455 (29.7)		6069 (36.3)	1168 (27.3)		462 (39.8)	88 (24.4)	

^a Non-capital area denotes residence outside of Seoul, Incheon metropolitan city, and Gyeonggi province, included in the Seoul Capital Area of South Korea.

^b Income levels, 1Q, 1st quintile (lowest); 2Q, 2nd quintile, 3Q, 3rd quintile; 4Q, 4th quintile, 5Q, 5th quintile (richest); values missing for 5320 individuals in primary series, 561 in 1st booster, and 19 in 2nd booster vaccination groups.

Abbreviations: CCI, Charlson comorbidity index; IQR, interquartile range

Table 2. Incidence rates (per 1000 person-days) and adjusted hazard ratios, after inverse probability of treatment weighting based on propensity scores, of all laboratory-confirmed and severe SARS-CoV-2 infections among NVX-CoV2373 and BNT162b2 vaccinations in South Korea, from February to December 2022.

Dose	NVX-CoV2373			BNT162b2			aHR (95% CI) ^b
	Event	Person-days	IR (95% CI)	Event	Person-days	IR (95% CI)	
Primary series							
All lab-confirmed infections	4884	3,029,053	1.53 (1.48–1.57)	4249	957,188	4.36 (4.23–4.49)	0.86 (0.82–0.91)
Severe infections ^a	50	3,119,176	0.02 (0.01–0.02)	27	1,014,824	0.03 (0.02–0.05)	0.80 (0.48–1.33)
1st booster							
All lab-confirmed infections	497	506,049	0.94 (0.86–1.03)	98	131,541	0.75 (0.57–0.86)	0.74 (0.61–0.90)
Severe infections	6	513,944	0.01 (0.01–0.03)	3	133,128	0.02 (0.01–0.07)	0.48 (0.12–1.92)
2nd booster							
All lab-confirmed infections	1	35,230	0.03 (0.00–0.20)	6	10,810	0.56 (0.25–1.24)	0.62 (0.01–59.02)
Severe infections	0	35,310	2.11E-13(0,infty)	1	10,884	0.09 (0.01–0.65)	Unable to assess

^a Severe SARS-CoV-2 infection was defined as intensive care unit (ICU) admission due to COVID-19 and death within 30 days of post-SARS-CoV-2 infection.

^b HR was calculated using inverse probability of treatment weighting (IPTW) based on the propensity score for receiving NVX-CoV2373, with IPTW adjustment for relative level of income, residential region (Seoul capital area or not), disability registration, prior COVID-19 infection history, and the Charlson comorbidity index assessed before the date of latest immunization.

Abbreviation, aHR, IPTW-adjusted hazard ratio; CI, confidence interval; ICU, intensive care unit; IR, incidence rate.